JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Japan ETF
EWJ
|
+$1.18B |
| 2 |
Vanguard Total International Bond ETF
BNDX
|
+$1.07B |
| 3 |
iShares Core MSCI EAFE ETF
IEFA
|
+$1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$963M |
| 5 |
Medtronic
MDT
|
+$799M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.5B |
| 2 |
Microsoft
MSFT
|
+$873M |
| 3 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$716M |
| 4 |
Chubb
CB
|
+$675M |
| 5 |
Lowe's Companies
LOW
|
+$661M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 23.13% |
| 2 | Financials | 15.03% |
| 3 | Technology | 12.86% |
| 4 | Healthcare | 9.44% |
| 5 | Consumer Discretionary | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2951
Corvus Pharmaceuticals
CRVS
$917M
| $2.52M | ﹤0.01% |
218,197
-27,264
| -11% | -$258K |
2016 Q2
7 quarters
|
|
2952
Quanta Services
PWR
$102B
| $2.52M | ﹤0.01% |
73,224
-209,065
| -74% | -$7.58M |
2013 Q2
19 quarters
|
|
|
ENLC
2953
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $2.52M | ﹤0.01% |
171,589
+111,147
| +184% | +$1.87M |
2013 Q2
19 quarters
|
|
|
ETFC
2954
CALL
DELISTED
E*Trade Financial Corporation
ETFC
| $2.49M | ﹤0.01% |
45,000
-41,600
| -48% | -$2.22M |
2017 Q3
2 quarters
|
|
2955
Healthcare Services Group
HCSG
$1.43B
| $2.49M | ﹤0.01% |
57,249
-51,452
| -47% | -$2.52M |
2013 Q2
19 quarters
|
|
2956
CALL
Neurocrine Biosciences
NBIX
$14.6B
| $2.49M | ﹤0.01% |
+30,000
| New | +$2.53M |
2018 Q1
0 quarters
|
|
|
2957
PUT
Neurocrine Biosciences
NBIX
$14.6B
| $2.49M | ﹤0.01% |
+30,000
| New | +$2.53M |
2018 Q1
0 quarters
|
|
|
UBNK
2958
DELISTED
United Financial Bancorp, Inc.
UBNK
| $2.48M | ﹤0.01% |
153,364
-13,255
| -8% | -$220K |
2013 Q2
19 quarters
|
|
2959
PUT
Trade Desk
TTD
$5.65B
| $2.48M | ﹤0.01% |
+500,000
| New | +$2.56M |
2018 Q1
0 quarters
|
|
|
CRZO
2960
DELISTED
Carrizo Oil & Gas Inc
CRZO
| $2.48M | ﹤0.01% |
155,099
-134,006
| -46% | -$2.52M |
2013 Q2
19 quarters
|
|
2961
Invesco Large Cap Growth ETF
PWB
$2.7B
| $2.48M | ﹤0.01% |
57,964
-4,551
| -7% | -$198K |
2016 Q1
8 quarters
|
|
2962
Howard Hughes
HHH
$4.24B
| $2.48M | ﹤0.01% |
18,688
-53,166
| -74% | -$6.52M |
2015 Q4
9 quarters
|
|
|
BPMC
2963
CALL
DELISTED
Blueprint Medicines
BPMC
| $2.48M | ﹤0.01% |
+27,000
| New | +$2.33M |
2018 Q1
0 quarters
|
|
|
BPMC
2964
PUT
DELISTED
Blueprint Medicines
BPMC
| $2.48M | ﹤0.01% |
+27,000
| New | +$2.33M |
2018 Q1
0 quarters
|
|
2965
First Trust Morningstar Dividend Leaders Index Fund
FDL
$7.54B
| $2.47M | ﹤0.01% |
87,626
+20,072
| +30% | +$590K |
2013 Q2
19 quarters
|
|
|
XYZ
2966
CALL
Block Inc
XYZ
$44.7B
| $2.46M | ﹤0.01% |
+50,000
| New | +$2.29M |
2018 Q1
0 quarters
|
|
|
BRKL
2967
DELISTED
Brookline Bancorp
BRKL
| $2.46M | ﹤0.01% |
151,661
-27,075
| -15% | -$443K |
2015 Q2
11 quarters
|
|
|
CWEN.A
2968
DELISTED
Clearway Energy Class A
CWEN.A
| $2.45M | ﹤0.01% |
148,855
-36,646
| -20% | -$634K |
2015 Q2
11 quarters
|
|
2969
Townsquare Media
TSQ
$83M
| $2.44M | ﹤0.01% |
308,135
+6,448
| +2% | +$47.4K |
2016 Q4
5 quarters
|
|
2970
State Street SPDR S&P Emerging Markets Dividend ETF
EDIV
$1.16B
| $2.44M | ﹤0.01% |
68,758
+52,657
| +327% | +$1.85M |
2015 Q4
9 quarters
|
|
|
PGNX
2971
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $2.44M | ﹤0.01% |
326,562
+237,992
| +269% | +$1.58M |
2017 Q4
1 quarter
|
|
2972
WisdomTree Europe SmallCap Dividend Fund
DFE
$162M
| $2.43M | ﹤0.01% |
34,808
+29,418
| +546% | +$2.11M |
2014 Q2
15 quarters
|
|
|
ATRI
2973
DELISTED
Atrion Corp
ATRI
| $2.43M | ﹤0.01% |
3,848
-688
| -15% | -$403K |
2016 Q3
6 quarters
|
|
2974
Scansource
SCSC
$1.24B
| $2.42M | ﹤0.01% |
68,071
+3,638
| +6% | +$124K |
2015 Q4
9 quarters
|
|
|
SVM
2975
Silvercorp Metals
SVM
$2.34B
| $2.42M | ﹤0.01% |
899,124
+50,400
| +6% | +$133K |
2017 Q2
3 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2018 Portfolio in Review
As of Q1 2018, JP Morgan Chase held 5,855 positions worth $467B, down 1.7% from $475B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q1 2018 filing shows 386 new, 1,953 increased, 2,569 reduced and 469 closed positions. Its largest new stake was Avaya Holdings Corp. Common Stock: 9,632,519 shares worth $216M. The largest sale was Apple, an estimated $1.5B.
By sector, the portfolio is most concentrated in Miscellaneous at 23% of assets, up from 22% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q1 2018 buy was Avaya Holdings Corp. Common Stock: 9,632,519 shares worth $216M.
- JP Morgan Chase added most to iShares MSCI Japan ETF in Q1 2018, an estimated $1.18B increase.
- JP Morgan Chase's biggest Q1 2018 reduction was Apple, cutting an estimated $1.5B.
- JP Morgan Chase fully exited Scripps Networks Interactive, Inc Common Class A in Q1 2018, selling an estimated $168M.
- JP Morgan Chase's ten largest holdings make up 18% of its $467B portfolio in Q1 2018.
- JP Morgan Chase opened 386 new positions and closed 469 in Q1 2018.
- JP Morgan Chase's portfolio value fell 1.7% quarter-over-quarter to $467B.
Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.